Strategies to prevent hypertrophic scar formation: a review of therapeutic interventions based on molecular evidence

Abstract

Once scar tissues mature, it is impossible for the surrounding tissue to regenerate normal dermal tissue. Therefore, it is essential to understand the fundamental mechanisms and establish effective strategies to inhibit aberrant scar formation. Hypertrophic scar formation is considered a result of the imbalance between extracellular matrix synthesis and degradation during wound healing. However, the underlying mechanisms of hypertrophic scar development are poorly understood. The purpose of this review was to outline the management in the early stage after wound healing to prevent hypertrophic scar formation, focusing on strategies excluding therapeutic agents of internal use. Treatment aimed at molecular targets, including cytokines, will be future options to prevent and treat hypertrophic scars. More basic studies and clinical trials, including combination therapy, are required to investigate the mechanisms and prevent hypertrophic scar formation.

Keywords

Hypertrophic scar / Therapy / Intervention / Cytokines

References

[1] Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: Pathomechanisms and current and emerging treatment strategies. Mol Med. 2011; 17: 113-25.

[2] Brewin MP, Lister TS. Prevention or treatment of hypertrophic burn scarring: A review of when and how to treat with the pulsed dye laser. Burns. 2014; 40: 797-804.

[3] Shi JH, Guan H, Shi S, Cai W-X, Bai X-Z, Hu X-L, et al. Protection against TGF-beta1-induced fibrosis effects of IL-10 on dermal fibroblasts and its potential therapeutics for the reduction of skin scarring. Arch Dermatol Res. 2013; 305: 341-52.

[4] Bloemen MC, van der Veer WM, Ulrich MM, van Zuijlen PP, Niessen FB, Middelkoop E. Prevention and curative management of hypertrophic scar formation. Burns. 2009; 35: 463-75.

[5] Niessen FB, Spauwen PH, Schalkwijk J, Kon M. On the nature of hypertrophic scars and keloids: A review. Plast Reconstr Surg. 1999; 104: 1435-58.

[6] Oliveira GV, Chinkes D, Mitchell C, Oliveras G, Hawkins HK, Herndon DN. Objective assessment of burn scar vascularity, erythema, pliability, thickness, and planimetry. Dernatol Surg. 2005; 31: 48-58.

[7] Bi M, Sun P, Li D, Dong Z, Chen Z. Intralesional injection of Botulinum toxin type a compared with intralesional injection of corticosteroid for the treatment of hypertrophic scar and keloid: A systematic review and meta-analysis. Med Sci Monit. 2019; 25: 2950-8.

[8] Hu L, Zou Y, Chang SJ, Qiu Y, Chen H, Gang M, et al. Effects of Botulinum toxin on improving facial surgical scars: A prospective, split-scar, double-blind, randomized controlled trial. Plast Reconstr Surg. 2018; 141: 646-50.

[9] Wang J, Liao Y, Xia J, Wang Z, Mo X, Feng J, et al. Mechanical micronization of lipoaspirates for the treatment of hypertrophic scars. Stem Cell Res Ther. 2019; 10: 42.

[10] Chu H, Wang Y, Wang X, Song X, Liu H, Li X. Effects of transplanted adipose derived stem cells on the expressions of alpha-SMA and DCN in fibroblasts of hypertrophic scar tissues in rabbit ears. Exp Ther Med. 2018; 16: 1729-34.

[11] Steinstraesser L, Flak E, Witte B, Ring A, Tilkorn D, Hauser J, et al. Pressure garment therapy alone and in combination with silicone for the prevention of hypertrophic scarring: Randomized controlled trial with intraindividual comparison. Plast Reconstr Surg. 2011; 128: 306e-13e.

[12] Jackson WM, Nesti LJ, Tuan RS. Mesenchymal stem cell therapy for attenuation of scar formation during wound healing. Stem Cell Res Ther. 2012; 3: 20.

[13] Ogawa R.Surgery for scar revision and reduction: From primary closure to flap surgery. Burns Trauma. 2019; 7: 7.

[14] He B, Wang Y, Shao N, Chang H, Cheng Y. Polymers modified with double-tailed fluorous compounds for efficient DNA and siRNA delivery. Acta Biomater. 2015; 22: 111-9.

[15] Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med. 1992; 176: 1375-9.

[16] Amadeu T, Braune A, Mandarim-de-Lacerda C, Porto LC, Desmoulière A, Costa A. Vascularization pattern in hypertrophic scars and keloids: A stereological analysis. Pathol Res Pract. 2003; 199: 469-73.

[17] Hinz B. The role of myofibroblasts in wound healing. Curr Res Transl Med. 2016; 64: 171-7.

[18] Hinz B. The myofibroblast: Paradigm for a mechanically active cell. J Biomech. 2010; 43: 146-55.

[19] Spyrou GE, Naylor IL. The effect of basic fibroblast growth factor on scarring. Br J Plast Surg. 2002; 55: 275-82.

[20] Placik OJ, Lewis VL, Jr. Immunologic associations of keloids. Surg Gynecol Obstet. 1992; 175: 185-93.

[21] Hayashida K, Fujioka M, Morooka S, Saijo H, Akita S. Effectiveness of basic fibroblast growth factor for pediatric hand burns. J Tissue Viability. 2016; 25: 220.

[22] Qiu SS, Dotor J, Hontanilla B. Effect of P144(R) (anti-TGF-beta) in an "in vivo" human hypertrophic scar model in nude mice. PLoS One. 2015; 10: e0144489.

[23] Chen Q, Zhao T, Xie X, Yu D, Wu L, Yu W, et al. MicroRNA-663 regulates the proliferation of fibroblasts in hypertrophic scars via transforming growth factor-beta1. Exp Ther Med. 2018; 16: 1311-7.

[24] Hong F, Wu N, Ge Y, Zhou Y, Shen T, Qiang Q, et al. Nanosized titanium dioxide resulted in the activation of TGF-beta/Smads/p38MAPK pathway in renal inflammation and fibration of mice. J Biomed Mater Res A. 2016; 104: 1452-61.

[25] Zhou B, Zeng S, Li L, Fan Z, Tian W, Li M, et al. Angiogenic factor with G patch and FHA domains 1 (Aggf1) regulates liver fibrosis by modulating TGF-beta signaling. Biochim Biophys Acta. 2016; 1862: 1203-13.

[26] Liu J, Wang Y, Pan Q, Su Y, Zhang Z, Han J, et al. Wnt/beta-catenin pathway forms a negative feedback loop during TGF-beta1 induced human normal skin fibroblast-to-myofibroblast transition. J Dermatol Sci. 2012; 65: 38-49.

[27] He S, Liu X, Yang Y, Huang W, Xu S, Yang S, et al. Mechanisms of transforming growth factor beta(1)/Smad signalling mediated by mitogen-activated protein kinase pathways in keloid fibroblasts. Br J Dermatol. 2010; 162: 538-46.

[28] He T, Bai X, Yang L, Fan L, Li Y, Su L, et al. Loureirin B inhibits hypertrophic scar formation via inhibition of the TGF-beta1-ERK/JNK pathway. Cell Physiol Biochem. 2015; 37: 666-76.

[29] Bailey AJ, Bazin S, Sims TJ, Le Lous M, Nicoletis C, Delaunay A. Characterization of the collagen of human hypertrophic and normal scars. Biochim Biophys Acta. 1975; 405: 412-21.

[30] Liu B, Liu Y, Wang L, Hou C, An M. The effects of pressure intervention on wound healing and scar formation in a Bama minipig model. Burns. 2019; 45: 413-22.

[31] Reno F, Grazianetti P, Cannas M. Effects of mechanical compression on hypertrophic scars: Prostaglandin E2 release. Burns. 2001; 27: 215-8.

[32] Li P, Li-Tsang CWP, Deng X, Wang X, Wang H, Zhang Y, et al. The recovery of post-burn hypertrophic scar in a monitored pressure therapy intervention programme and the timing of intervention. Burns. 2018; 44: 1451-67.

[33] Stella M, Castagnoli C, Gangemi EN. Postburn scars: An update. Int J Low Extrem Wounds. 2008; 7: 176-81.

[34] Oliveira GV, Hawkins HK, Chinkes D, Burke A, Tavares AK, Ramos-e-Silva M, et al. Hypertrophic versus non hypertrophic scars compared by immunohistochemistry and laser confocal microscopy: Type I and III collagens. Int Wound J. 2009; 6: 445-52.

[35] Ahmad A, Herndon DN, Szabo C. Oxandrolone protects against the development of multiorgan failure, modulates the systemic inflammatory response and promotes wound healing during burn injury. Burns. 2019; 45: 671-81.

[36] Cho YS, Jeon JH, Hong A, Yang HT, Yim H, Cho YS, et al. The effect of burn rehabilitation massage therapy on hypertrophic scar after burn: A randomized controlled trial. Burns. 2014; 40: 1513-20.

[37] Suetake T, Sasai S, Zhen YX, Ohi T, Ogami H. Functional analyses of the stratum corneum in scars. Sequential studies after injury and comparison among keloids, hypertrophic scars, and atrophic scars. Arch Dermatol. 1996; 132: 1453-8.

[38] Terunuma A, Aiba S, Tagami H. Cytokine mRNA profiles in cultured human skin component cells exposed to various chemicals: A simulation model of epicutaneous stimuli induced by skin barrier perturbation in comparison with that due to exposure to haptens or irritant. J Dermatol Sci. 2001; 26: 85-93.

[39] Mustoe TA. Evolution of silicone therapy and mechanism of action in scar management. Aesthetic Plast Surg. 2008; 32: 82-92.

[40] Phillips TJ, Gerstein AD, Lordan V. A randomized controlled trial of hydrocolloid dressing in the treatment of hypertrophic scars and keloids. Dermatol Surg. 1996; 22: 775-8.

[41] Robson MC, Kucan JO, Paik KI, Eriksson E. Prevention of dermal ischemia after thermal injury. Arch Surg. 1978; 113: 621.

[42] Kull FC, Jr. Reduction in tumor necrosis factor receptor affinity and cytotoxicity by glucocorticoids. Biochem Biophys Res Commun. 1988; 153: 402-9.

[43] Costas M, Trapp T, Pereda MP, Sauer J, Rupprecht R, Nahmod VE, et al. Molecular and functional evidence for in vitro cytokine enhancement of human and murine target cell sensitivity to glucocorticoids. TNF-alpha priming increases glucocorticoid inhibition of TNF-alpha-induced cytotoxicity/apoptosis. J Clin Invest. 1996; 98: 1409-16.

[44] Sobec RL, Fodor L, Bodog F. Topical Oxandrolone reduces ear hypertrophic scar formation in rabbits. Plast Reconstr Surg. 2019; 143: 481-7.

[45] Mustoe TA, Gurjala A. The role of the epidermis and the mechanism of action of occlusive dressings in scarring. Wound Repair Regen. 2011; 19(Suppl 1): s16-21.

[46] Thomas S, Wolf SE, Murphy KD, Chinkes DL, Herndon DN. The long-term effect of oxandrolone on hepatic acute phase proteins in severely burned children. J Trauma. 2004; 56: 37-44.

[47] Grunfeld C, Kotler DP, Dobs A, Glesby M, Bhasin S. Oxandrolone in the treatment of HIV-associated weight loss in men: A randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr. 2006; 41: 304-14.

[48] Orr R, Fiatarone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: Review of efficacy and safety. Drugs. 2004; 64: 725-50.

[49] Li H, Guo Y, Yang Z, Roy M, Guo Q. The efficacy and safety of oxandrolone treatment for patients with severe burns: A systematic review and meta-analysis. Burns. 2016; 42: 717-27.

[50] Alster TS, Nanni CA. Pulsed dye laser treatment of hypertrophic burn scars. Plast Reconstr Surg. 1998; 102: 2190-5.

[51] Dierickx CC, Casparian JM, Venugopalan V, Farinelli A, Anderson RR. Thermal relaxation of port-wine stain vessels probed in vivo: The need for 1-10-millisecond laser pulse treatment. J Invest Dermatol. 1995; 105: 709-14.

[52] Clayton JL, Edkins R, Cairns BA, Hultman CS. Incidence and management of adverse events after the use of laser therapies for the treatment of hypertrophic burn scars. Ann Plast Surg. 2013; 70(5): 500.

[53] Jung JY, Jeong JJ, Roh HJ, Cho SH, Chung KY, Lee WJ, et al. Early postoperative treatment of thyroidectomy scars using a fractional carbon dioxide laser. Dermatol Surg. 2011; 37: 217-23.

[54] Kim SG, Kim EY, Kim YJ, Lee SI. The efficacy and safety of ablative fractional resurfacing using a 2,940-nm Er:YAG laser for traumatic scars in the early posttraumatic period. Arch Plast Surg. 2012; 39: 232-7.

[55] Qu L, Liu A, Zhou L, He C, Grossman PH, Moy RL, et al. Clinical and molecular effects on mature burn scars after treatment with a fractional CO(2) laser. Lasers Surg Med. 2012; 44: 517-24.

[56] Rodriguez-Menocal L, Davis SS, Becerra S, Salgado M, Gill J, Valdes J, et al. Assessment of ablative fractional CO2 laser and Er:YAG laser to treat hypertrophic scars in a red Duroc pig model. J Burn Care Res. 2018; 39: 954-62.

[57] Sruthi K, Chelakkot PG, Madhavan R, Nair RR, Dinesh M. Single-fraction radiation: A promising adjuvant therapy to prevent keloid recurrence. J Cancer Res Ther. 2018; 14: 1251-5.

[58] Ogawa R, Akaishi S. Endothelial dysfunction may play a key role in keloid and hypertrophic scar pathogenesis-Keloids and hypertrophic scars may be vascular disorders. Med Hypotheses. 2016; 96: 51-60.

[59] van de Kar AL, Kreulen M, van Zuijlen PP, Oldenburger F. The results of surgical excision and adjuvant irradiation for therapy-resistant keloids: A prospective clinical outcome study. Plast Reconstr Surg. 2007; 119: 2248-54.

[60] Xu J, Yang E, Yu NZ, Long X. Radiation therapy in keloids treatment: History, strategy, effectiveness, and complication. Chin Med J (Engl). 2017; 130: 1715-21.

[61] Renz P, Hasan S, Gresswell S, Hajjar RT, Trombetta M, Fontanesi J. Dose effect in adjuvant radiation therapy for the treatment of resected keloids. Int J Radiat Oncol Biol Phys. 2018; 102: 149-54.

[62] Ji J, Tian Y, Zhu YQ, Zhang LY, Ji SJ, Huan J, et al. Ionizing irradiation inhibits keloid fibroblast cell proliferation and induces premature cellular senescence. J Dermatol. 2015; 42: 56-63.

[63] Guix B.Radiotherapy concepts for keloids current options and clinical results. Radiother Oncol. 2004; 71: 15.

[64] Setler PE. Therapeutic use of botulinum toxins: Background and history. Clin J Pain. 2002; 18: 119-24.

[65] Gassner HG, Sherris DA. Chemoimmobilization: Improving predictability in the treatment of facial scars. Plast Reconstr Surg. 2003; 112: 1464-6.

[66] Omranifard M, Heidari M, Farajzadegan Z, Niktabar MR, Motamedi N. Botulinum toxin and burn induces contracture. Arch Plast Surg. 2016; 43: 609-11.

[67] Wilson AM. Use of botulinum toxin type a to prevent widening of facial scars. Plast Reconstr Surg. 2006; 117: 1758-66, discussion 67-8.

[68] Jeong HS, Lee BH, Sung HM, Park SY, Ahn DK, Jung MS, et al. Effect of Botulinum toxin type a on differentiation of fibroblasts derived from scar tissue. Plast Reconstr Surg. 2015; 136: 171e-8e.

[69] Xiao Z, Zhang F, Lin W, Zhang M, Liu Y. Effect of botulinum toxin type a on transforming growth factor beta1 in fibroblasts derived from hypertrophic scar: A preliminary report. Aesthetic Plast Surg. 2010; 34: 424-7.

[70] Hao R, Li Z, Chen X, Ye W. Efficacy and possible mechanisms of Botulinum toxin type a on hypertrophic scarring. J Cosmet Dermatol. 2018; 17: 340-6.

[71] Shi J, Li J, Guan H, Cai W, Bai X, Fang X, et al. Anti-fibrotic actions of interleukin-10 against hypertrophic scarring by activation of PI3K/AKT and STAT3 signaling pathways in scar-forming fibroblasts. PLoS One. 2014; 9: e98228.

[72] Sabat R, Grutz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010; 21: 331-44.

[73] Glocker EO, Kotlarz D, Klein C, Shah N, Grimbacher B. IL-10 and IL-10 receptor defects in humans. Ann N Y Acad Sci. 2011; 1246: 102-7.

[74] Lee TH, Lee GW, Ziff EB, Vilcek J. Isolation and characterization of eight tumor necrosis factor-induced gene sequences from human fibroblasts. Mol Cell Biol. 1990; 10: 1982-8.

[75] Zheng J, Song F, Lu SL, Wang XQ. Dynamic hypoxia in scar tissue during human hypertrophic scar progression. Dermatol Surg. 2014; 40: 511-8.

[76] Wang P, Jiang LZ, Xue B. Recombinant human endostatin reduces hypertrophic scar formation in rabbit ear model through down-regulation of VEGF and TIMP-1. Afr Health Sci. 2016; 16: 542-53.

[77] Kwak DH, Bae TH, Kim WS, Kim HK. Anti-vascular endothelial growth factor (Bevacizumab) therapy reduces hypertrophic scar formation in a rabbit ear wounding model. Arch Plast Surg. 2016; 43: 491-7.

[78] Shen R, Li TZ, Qi SH, Liang HZ, Xu YB, Xie JL, et al. A research of endothelial cell-targeted therapy for cure of hypertrophic scar. Zhonghua Zheng Xing Wai Ke Za Zhi. 2003; 19: 254-7.

[79] Yue YG, Jiang CW, Li PY, Zhou S. Influence of the VEGF antibody targeted vascular therapy on the expression of collagen type I in hyperplastic. Zhonghua Shao Shang Za Zhi. 2006; 22: 427-30.

[80] Song Y, Yu Z, Song B, Gui S, Lei L, Ma X, et al. Usnic acid inhibits hypertrophic scarring in a rabbit ear model by suppressing scar tissue angiogenesis. Biomed Pharmacother. 2018; 108: 524-30.

[81] Song Y, Dai F, Zhai D, Dong Y, Zhang J, Lu B, et al. Usnic acid inhibits breast tumor angiogenesis and growth by suppressing VEGFR2-mediated AKT and ERK1/2 signaling pathways. Angiogenesis. 2012; 15: 421-32.

[82] Hoerst K, van den Broek L, Sachse C, Klein O, von Fritschen U, Gibbs S, et al. Regenerative potential of adipocytes in hypertrophic scars is mediated by myofibroblast reprogramming. J Mol Med (Berl). 2019; 97: 761-75.

[83] Klinger M, Caviggioli F, Klinger FM, Giannasi S, Bandi V, Banzatti B, et al. Autologous fat graft in scar treatment. J Craniofac Surg. 2013; 24(5): 1610.

[84] Bruno A, Delli Santi G, Fasciani L, Cempanari M, Palombo M, Palombo P. Burn scar lipofilling: Immunohistochemical and clinical outcomes. J Craniofac Surg. 2013; 24: 1806-14.

[85] Wang G, Ren Y, Cao W, Yang Y, Li S. Liposculpture and fat grafting for aesthetic correction of the gluteal concave deformity associated with multiple intragluteal injection of penicillin in childhood. Aesthetic Plast Surg. 2013; 37: 39-45.

[86] Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002; 13: 4279-95.

[87] Zhang Q, Liu LN, Yong Q, Deng JC, Cao WG. Intralesional injection of adipose-derived stem cells reduces hypertrophic scarring in a rabbit ear model. Stem Cell Res Ther. 2015; 6: 145.

[88] Klinger M, Marazzi M, Vigo D, Torre M. Fat injection for cases of severe burn outcomes: A new perspective of scar remodeling and reduction. Aesthetic Plast Surg. 2008; 32: 465-9.

[89] Guisantes E, Fontdevila J, Rodriguez G. Autologous fat grafting for correction of unaesthetic scars. Ann Plast Surg. 2012; 69: 550-4.

[90] Ferrini MG, Vernet D, Magee TR, Shahed A, Qian A, Rajfer J, et al. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide. 2002; 6: 283-94.

[91] Liu YL, Liu WH, Sun J, Hou TJ, Liu YM, Liu HR, et al. Mesenchymal stem cell-mediated suppression of hypertrophic scarring is p53 dependent in a rabbit ear model. Stem Cell Res Ther. 2014; 5: 136.

[92] Bi X, Tong C, Dockendorff A, Bancroft L, Gallagher L, Guzman G, et al. Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis. 2008; 29: 1435-40.

[93] Wang J, Ding J, Jiao H, Honardoust D, Momtazi M, Shankowsky HA, et al. Human hypertrophic scar-like nude mouse model: Characterization of the molecular and cellular biology of the scar process. Wound Repair Regen. 2011; 19: 274-85.

[94] Nabai L, Ghahary A. Hypertrophic scarring in the rabbit ear: A practical model for studying dermal fibrosis. Methods Mol Biol. 2017; 1627: 81-9.